Corvus Pharmaceuticals Inc
CRVS
NASDAQ
Biotechnology
$14.89
USD
-0.25 (-1.65%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.28B
Volume 777.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-54.13M
TTM
-19.9%
YoY
Operating Cash Flow
$-44.53M
TTM
-54.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.4 | 2.1 | 2.3 | 3.7 | 3.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.3 | 10.6 | 12.2 | 14.9 | 19.3 |
Operating Income | -10.3 | -10.6 | -12.2 | -14.9 | -19.3 |
EBITDA | -10.2 | -10.5 | -12.2 | -14.8 | -19.3 |
Other Income / Expense | 1.6 | 0.0 | -2.0 | 0.0 | -0.7 |
Total Other Income / Expense | 2.3 | 0.7 | -1.4 | 1.8 | 1.3 |
Income Before Income Taxes | -8.0 | -9.8 | -13.6 | -13.1 | -18.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.0 | -10.2 | -12.3 | -13.7 | -18.0 |
Consolidated Net Income / Loss | -8.0 | -10.2 | -12.3 | -13.7 | -18.0 |
Net Income Attributable to Common Shareholders | -8.0 | -10.2 | -12.3 | -13.7 | -18.0 |
Basic EPS | -$0.10 | -$0.12 | -$0.15 | -$0.15 | -$0.19 |
Diluted EPS | -$0.10 | -$0.12 | -$0.15 | -$0.15 | -$0.19 |
Basic Shares Outstanding | 77.8M | 82.8M | 83.1M | 90.0M | 92.4M |
Diluted Shares Outstanding | 77.8M | 82.8M | 83.2M | 90.0M | 92.4M |